TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataKi: 0.0398nMAssay Description:Inhibition of integrin alphavbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Glaxosmithkline R&D
Curated by ChEMBL
Glaxosmithkline R&D
Curated by ChEMBL
Affinity DataKi: 0.0794nMAssay Description:Inhibition of PI3Kdelta (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HT...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataKi: 0.107nMAssay Description:Inhibition of integrin alphavbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Glaxosmithkline R&D
Curated by ChEMBL
Glaxosmithkline R&D
Curated by ChEMBL
Affinity DataKi: 0.126nMAssay Description:Inhibition of PI3Kdelta (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HT...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataKi: 0.174nMAssay Description:Inhibition of integrin alphavbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataKi: 2nMAssay Description:Inhibition of integrin alphavbeta1 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataKi: 10nMAssay Description:Inhibition of integrin alphavbeta5 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataKi: 40nMAssay Description:Inhibition of integrin alphavbeta3 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.100nMAssay Description:V79 cell lines stably expressing the either the human CYP11B2 or the human CYP11B1 enzyme were generated using a standard transfection protocol. V79 ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.100nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.200nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.300nMAssay Description:V79 cell lines stably expressing the either the human CYP11B2 or the human CYP11B1 enzyme were generated using a standard transfection protocol. V79 ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.300nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.300nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.450nMAssay Description:V79 cell lines stably expressing the either the human CYP11B2 or the human CYP11B1 enzyme were generated using a standard transfection protocol. V79 ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:V79 cell lines stably expressing the either the human CYP11B2 or the human CYP11B1 enzyme were generated using a standard transfection protocol. V79 ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.700nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.700nMAssay Description:Inhibition of human dCKMore data for this Ligand-Target Pair
Affinity DataIC50: 0.700nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.700nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Glaxosmithkline
Curated by ChEMBL
Glaxosmithkline
Curated by ChEMBL
Affinity DataIC50: 0.794nMAssay Description:Inhibition of recombinant human full-length N-terminal His6-tagged p110delta/human recombinant full-length untagged p85alpha expressed in baculovirus...More data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 0.800nMAssay Description:Inhibition of integrin alphavbeta3 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.900nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 0.900nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of human dCKMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of human dCKMore data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibition of ligand binding to integrin alphavbeta8 (unknown origin) expressed in baculovirus expression system after 2 hrs by solid-phase assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of ligand binding to integrin alphavbeta1 (unknown origin) expressed in baculovirus expression system after 2 hrs by solid-phase assayMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 1.40nMAssay Description:Inhibition of ligand binding to integrin alphavbeta6 (unknown origin) expressed in baculovirus expression system after 2 hrs by solid-phase assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of integrin alphavbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:Factor XIIa activity determinations were made in 50 mM HEPES buffer containing 150 mM NaCl, 5 mM CaCl2, and 0.1% PEG 8000 (polyethylene glycol; JT Ba...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:V79 cell lines stably expressing the either the human CYP11B2 or the human CYP11B1 enzyme were generated using a standard transfection protocol. V79 ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Glaxosmithkline
Curated by ChEMBL
Glaxosmithkline
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Inhibition of VPS34 in human HL60 cell extract measured after 2 hrs by kinobeads based pull down assayMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Glaxosmithkline R&D
Curated by ChEMBL
Glaxosmithkline R&D
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Inhibition of PI3Kdelta in human HL60 cell extract measured after 2 hrs by kinobeads based pull down assayMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Glaxosmithkline
Curated by ChEMBL
Glaxosmithkline
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Inhibition of recombinant human full-length N-terminal His6-tagged p110delta/human recombinant full-length untagged p85alpha expressed in baculovirus...More data for this Ligand-Target Pair